Business Wire

ROKA Launches Ultralight Advanced Performance Eyewear with World-Class Roster of Athletes


ROKA Sports Inc., the Austin, TX based performance multisport company, has announced the release of its new Advanced Performance for Extreme Conditions (A.P.EX) line of eyewear. The collection was designed from scratch for the athlete who requires maximum field of view, protection, ultra-lightweight, and seamless fit and retention. The Advanced Performance collection is incredibly versatile, coming in five styles and up to ten lens tint options, so athletes can completely customize their eyewear to meet their specific needs.

This press release features multimedia. View the full release here:

(Photo: Business Wire)

(Photo: Business Wire)

The unique design of ROKA’s Advanced Performance collection is the realization of more than two years of stealth R&D by ROKA’s eyewear division, an all-star team of designers and engineers based in Irvine, California, who were assembled specifically for this mission and were drawn from Apple, Oakley, Under Armour, and other leading brands. Upon formation, ROKA Co-Founders Rob Canales and Kurt Spenser challenged the team, which has over 110 years combined experience making performance eyewear, to design and build the best sport optics on the planet from the inside out, with a primary focus on function in extreme conditions.

“This is truly a breakthrough in performance eyewear,” says ROKA Co-Founder and CEO Rob Canales. “We build products for the most demanding athletes in the world, and through meticulous attention to detail and the aggregation of incremental gains, our team has delivered. While other brands are cutting performance and quality to satisfy their monopolist owners, we’ve gone all in with a truly independent line that is with uncompromising performance.”

The A.P.EX line consists of three different frame options, with multiple lens height configurations: The SL-1, SL-1x, SR-1, SR-1x, and TL-1. Weighing in at only 21 – 25 grams, every style features ultra-lightweight materials and construction without compromising durability. An adjustable titanium core offers a customized fit, and advanced materialization with ROKA’s patented GEKO™ technology on the nose pads and temples ensure a rock solid fit under the most adverse training and racing conditions.

All five styles feature premium nylon lens options by Carl Zeiss Vision that come standard with market-leading hydrophobic, oleophobic, anti-scratch, anti-fog, and anti-reflectance coatings. Whether riding in the glaring sun or running through rain and snow, athletes will have multiple contrast and mirror options for the specific demands of the day.

“The moment I slipped on the ROKA sunglasses, I knew they had set a new standard in the performance eyewear market,” says eight-time triathlon world champion Javier Gómez. “There is nothing else that comes close in terms of weight, security, and optics. ROKA’s technical apparel and goggles have been a secret weapon for me in multiple world championships. I’m thrilled to have that same world-beating standard for my eyewear.”

Gómez is one of more than 40 elite athletes to debut the Advanced Performance eyewear in 2018. Regardless of the arena or challenge, ROKA eyewear is designed for athletes seeking to redefine standards, to break barriers, and to find every advantage possible. Within a few weeks of their release, Carlos Sainz drove them to victory at the Dakar Rally in South America, and Esmee Visser took them to the top of the Olympic podium in speed skating in PyeongChang.

“I first tried ROKA sunglasses in January—about a month before the Olympics,” Visser says. “The sunglasses I used previously were good, but I always had problems with my eyes tearing up. With ROKA’s SR-1 sunglasses, I had better protection and fewer tears, and they weighed less, so it was an easy decision to use them at the Olympics.”

Advanced Performance optics have also helped pro cyclists Bryan Coquard and Magnus Cort Nielsen reach the top of the World Tour podium in 2018, out-sprinting the best cyclists in the world. They will also be the eyewear of choice for Dan Martin this July when he attempts to become the second Irishman ever to win the Tour de France.

“I pride myself on being innovative and finding every little advantage that I can,” says Martin. “When I looked into the ROKA brand, I knew they fit with my philosophy.” Martin says. “From the moment I put on the Advanced Performance eyewear, I knew ROKA had designed something truly better. The weight and fit is unlike anything else I’ve ever tried.”

Remaining true to its DNA as the top endurance sports brand in the world and its roots as the leading high-performance triathlon brand, a large number of triathletes including Ironman Linsey Corbin, the fastest American woman at the Iron distance, have chosen ROKA as their eyewear partner for the hardest single-day endurance event in the world, joining Gómez and original ROKA athlete Jesse Thomas.

The mission to create the most advanced high-performance eyewear on the planet began with the challenge presented by ROKA’s first sponsored athlete, Jesse Thomas, who wanted to blend his classic style of retro aviators with the lightweight fit and protection of high-performance optics.

“We’re passionate about designing the most advanced high performance products on the market for athletes who seek to redefine the standard. We are a dedicated team of creators, designers, engineers, and athletes who share that mission. We are incredibly proud of the results thus far. Stay tuned.” says ROKA Co-Founder and Chief Creative Officer, Kurt Spenser. “This incredible group of athletes all share a commitment to perform at the highest level in their respective arenas, and to go beyond what was previously thought possible. We work tirelessly to honor that commitment by delivering the most advanced eyewear in the world.”

Each of the five styles in the Advanced Performance collection has been optimized for specific use cases to accommodate a range of fit and function preferences. With its rimless design, the SL-1 and SL-1x provide athletes a completely unobstructed field of view and venting, even while in the extreme forward aero position under the hottest conditions. The SR-1 and SR-1x are designed for security, confidence, and speed for the absolutely fastest training and racing days, and they’re equally as comfortable underneath a helmet as they are out on the run. The sleek and stylish TL-1 is a high-performing, twin-lens sport frame that offers versatility, security, and ultralight performance, and is sure to be an instant favorite across a variety of applications.

All five styles feature ROKA’s patented GEKO™ pads on the nose and temples for optimal traction and comfort, as well as titanium core wires in the temples to provide a customized fit for every athlete. The SL-1, SL-1x, SR-1 and SR-1x feature nine interchangeable accessory lens options, so athletes can quickly change the tint to take on the specific conditions of any ride, run or race. The polarized lens options in the TL-1 are cut for superior optics and exceed all industry standards for polarization efficiency. ROKA’s proprietary polarization process minimizes distortion and warpage better than any other eyewear on the market.

“When we debuted our first line of eyewear in 2016, we sought to be the first brand to blend classic optical style with high performance and comfort,” said James Oman, Vice President of Engineering. “With the Advanced Performance line, we are pushing beyond limits to create a new standard of optics, protection and versatility. It’s a bold new category of eyewear that will forever change what athletes expect from a pair of sunglasses.”

About ROKA

ROKA started in a garage in Austin, Texas with humble beginnings and laser-beam focus. Our mission is to unlock human potential. To equip, empower, inspire and ignite. We serve those who seek to redefine the standard, to push themselves to the limit – whatever and wherever that may be. When we see an opportunity to innovate, to challenge the status quo, to disrupt a complacent or monopolistic market, we go all in.

Since our launch in 2013, our athletes have won over a dozen world titles and have been instrumental in the design and development of our patented and award-winning products. In 2016, we were proud to send 18 athletes to the Rio Olympics, and even prouder to take home Gold and Bronze. This year in PyeongChang, we continued the tradition, with ROKA athletes taking home Olympic Gold and Bronze in our most cutting edge products.

With our debut eyewear collection in late 2016, we have set a new bar by making ultralight performance eyewear with zero compromise on style, and with a patented design for sunglasses that stay put on your face even during the most extreme training and racing. Featuring a suite of the world's most advanced materials and patented technologies, our award-winning Ultralight Performance Eyewear delivers on our promise to create the finest technical equipment on the planet, full stop. For more information, visit

Contact information

Diane Thibert
VP Communications & Public Relations
(310) 804-2400

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Elliott Welcomes Imminent Bezeq Board Overhaul and New Era for Strong Independent Governance23.3.2018 16:05Pressemelding

Elliott Advisors (UK) Limited (“Elliott”), which advises funds which collectively hold a significant economic interest in Bezeq The Israeli Telecommunication Corporation Ltd. (“Bezeq” or the “Company”), welcomes the proposed governance reforms announced by Bezeq last night. In its initial letter to Bezeq Interim Chairman David Granot, dated January 16, 2018, Elliott outlined the urgent need to address the Company’s serious corporate governance issues, and called for changes at the Board level that result in “the right mixture of expertise, independence and integrity for the future.” Elliott stated then, and reiterates now, its belief that “there is significant value to be unlocked if the right steps are taken to improve its corporate governance.” Bezeq has strong business fundamentals, an exemplary workforce, and great potential. Following yesterday’s announcement, Elliott highlights the changes that have occurred since January 16th. Taken together, these amount to a revolution in the

Clovis Oncology Initiates Early Access Program for Rucaparib as Treatment and as Maintenance Therapy in Recurrent Ovarian Cancer in Europe23.3.2018 12:52Pressemelding

Clovis Oncology, Inc. (NASDAQ:CLVS) today announced the initiation of an early access program in Europe for rucaparib for treatment and as maintenance therapy in recurrent ovarian cancer. The program will be overseen and implemented by Caligor Coghlan, which specializes in early access to medicines. The program, to be known as the Rucaparib Access Program (RAP), will enable participation from certain countries in Europe, where permitted by applicable rules, procedures and regulatory authorities. The RAP protocol allows for rucaparib treatment of an individual patient with third-line or greater BRCA mutant epithelial, fallopian tube, or primary peritoneal ovarian cancer who has platinum-sensitive disease and is unable to tolerate further platinum-based chemotherapy or has platinum-resistant disease and needs treatment with single agent rucaparib. The RAP protocol will also provide access to rucaparib for maintenance therapy of an individual patient with recurrent epithelial ovarian, fal

CHMP Grants Positive Opinion for Clovis Oncology’s Rubraca® (rucaparib) Tablets23.3.2018 12:50Pressemelding

Clovis Oncology, Inc. (NASDAQ: CLVS) today announced that the European Union’s (EU) European Medicines Agency (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion recommending the granting of a conditional marketing authorization for Rubraca as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The European Marketing Authorization application for the treatment indication was based on objective response rate and duration of response results from two multicenter, single-arm, open-label clinical trials, Study 10 and ARIEL2, in women with advanced BRCA mutant ovarian cancer who had progressed after two or more prior chemotherapies. “The recommendation

Janssen Announces Positive CHMP Opinion for JULUCATM▼ (dolutegravir/rilpivirine)23.3.2018 12:46Pressemelding

The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a Positive Opinion recommending marketing authorisation for JULUCA™ (dolutegravir 50mg [ViiV Healthcare UK Ltd]/rilpivirine 25mg [Janssen Sciences Ireland UC]). Dolutegravir/rilpivirine is a single-pill, two-drug regimen for the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults who are virologically suppressed (HIV-1 RNA <50 c/mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor (NNRTI) or integrase strand transfer inhibitor (INSTI).1 “We are delighted to be one step closer to bringing JULUCA™ to people living with HIV in Europe,” said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, LLC. “Building on our 25-year c

Aitheon Executives Educate World Leaders on Benefits, Challenges of AI at the Annual World Government Summit in Dubai23.3.2018 12:00Pressemelding

Aitheon, makers of the world’s first blockchain-powered platform to solve real problems by integrating AI, robotics, IoT, human specialists and cryptocurrency, announced today that executives from the company held a series of high-level briefings with world leaders at the Annual World Government Summit in Dubai. Briefings covered the benefits and challenges of AI, and revolutionary new solutions to world challenges made possible by transformative new technologies. (Read the full release at This press release features multimedia. View the full release here: Aitheon founder and CEO, Andrew Archer, and Chief Strategy Officer, Ryan Burleson, were invited to brief leaders at the Summit by Cyrus Hodes, Co-founder and Director of the AI Initiative, an undertaking of the Future Society at Harvard University’s Kennedy School. Archer and Burleson addressed a variety of AI-related topics, including the impact of AI on

ViiV Healthcare Gains CHMP Positive Opinion for Juluca (dolutegravir/rilpivirine) in Europe23.3.2018 11:27Pressemelding

ViiV Healthcare, the global specialist HIV company, majority owned by GlaxoSmithKline, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the European Committee for Medicinal Products for Human Use (CHMP) has issued a Positive Opinion recommending marketing authorisation for Juluca (dolutegravir/rilpivirine) for the treatment of HIV infection in adults who are virologically suppressed (HIV-1 RNA less than 50 copies per mL) on a stable antiretroviral regimen for at least six months with no history of virological failure and no known or suspected resistance to any non-nucleoside reverse transcriptase inhibitor or integrase inhibitor. The 2-drug regimen comprises dolutegravir 50mg (ViiV Healthcare) and rilpivirine 25mg (Janssen Sciences Ireland UC). Deborah Waterhouse, Chief Executive Officer at ViiV Healthcare commented: “Today is an important milestone for people living with HIV in Europe. It takes us a step closer to offering the first, single-pill, 2-drug regi